Email Us
Call Us
AUSTIN, Texas – December 19, 2017 – Altogen delivery technology is cited in Molecular Therapy — Nucleic Acids research on reversing the expression of aging-associated molecules through microRNA transfection, adding regenerative medicine and aging biology to the fields in which the platform appears in the peer-reviewed record. Longevity and regenerative programs face the same preclinical requirements as oncology programs, and often face them with less established infrastructure: reproducible delivery, confirmed target engagement, credible in vivo models, and safety data adequate for an eventual IND. Altogen Labs provides that infrastructure as a single integrated service.
Capabilities relevant to regenerative and cell therapy sponsors include teratoma formation and analysis services for embryonic stem (ES) and induced pluripotent stem (iPS) cell characterization — a required assessment of pluripotency and tumorigenic risk before cell-based therapies advance — alongside stable cell line development, CRISPR/Cas9 gene editing, RNAi and microRNA delivery, cryopreservation and GLP-compliant master and working cell bank generation, and comprehensive in vivo toxicology. Altogen Labs scientists understand the risks and complexities associated with stem cell therapeutics and design studies to identify complications, interactions, and factors that could limit therapeutic viability, examining the influence of growth factors, hormones, genetic modification, and delivery route on teratoma formation and composition.
The company has conducted preclinical contract research continuously since 2009 from its GLP-compliant, IACUC-regulated laboratory in Austin, Texas, supporting sponsors from study design through patent filing and regulatory submission, with 100% of resulting intellectual property retained by the client.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide. The company maintains a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Kim et al., “Reverse Expression of Aging-Associated Molecules through Transfection of miRNAs,” Molecular Therapy — Nucleic Acids, 2017